Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mikaela McCabe
Institutions:
Barnes-Jewish Hospital,
The University of Texas MD Anderson Cancer Center
Observed institutions:
Barnes-Jewish Hospital,
The University of Texas MD Anderson Cancer Center,
University of Health Sciences and Pharmacy
ORCID:
0009-0004-3223-0342
Observed ORCID:
0009-0004-3223-0342
OpenAlex ID:
A5061828200
The threat of multidrug-resistant/extensively drug-resistant Gram-negative respiratory infections: another pandemic
2022
·
Daniel Reynolds
, Jason P. Burnham
, et al.
·
European Respiratory Review
·
113
PDF
Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial
2026
·
Jayastu Senapati
, Hagop M. Kantarjian
, et al.
·
Blood Cancer Discovery
·
5
PDF
CLL-823: Venetoclax Initiation, Monitoring, and Interventions After Acalabrutinib Lead-In for Chronic Lymphocytic Leukemia
2026
·
Emily Lee
, Alexandra Lovell
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
POSTER: CLL-823: Venetoclax Initiation, Monitoring, and Interventions After Acalabrutinib Lead-In for Chronic Lymphocytic Leukemia
2026
·
Emily Lee
, Alexandra Lovell
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Table S20 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial
2026
·
Jayastu Senapati
, Hagop M. Kantarjian
, et al.
Figure S7 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial
2026
·
Jayastu Senapati
, Hagop M. Kantarjian
, et al.
Table S5 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial
2026
·
Jayastu Senapati
, Hagop M. Kantarjian
, et al.
Figure S6 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial
2026
·
Jayastu Senapati
, Hagop M. Kantarjian
, et al.
Figure S13 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial
2026
·
Jayastu Senapati
, Hagop M. Kantarjian
, et al.
Figure S18 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial
2026
·
Jayastu Senapati
, Hagop M. Kantarjian
, et al.
Figure S14 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial
2026
·
Jayastu Senapati
, Hagop M. Kantarjian
, et al.
Figure S9 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial
2026
·
Jayastu Senapati
, Hagop M. Kantarjian
, et al.
Table S8 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial
2026
·
Jayastu Senapati
, Hagop M. Kantarjian
, et al.
Table S15 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial
2026
·
Jayastu Senapati
, Hagop M. Kantarjian
, et al.
Table S18 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial
2026
·
Jayastu Senapati
, Hagop M. Kantarjian
, et al.
Data from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial
2026
·
Jayastu Senapati
, Hagop M. Kantarjian
, et al.
Table S17 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial
2026
·
Jayastu Senapati
, Hagop M. Kantarjian
, et al.
Table S11 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial
2026
·
Jayastu Senapati
, Hagop M. Kantarjian
, et al.
Table S6 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial
2026
·
Jayastu Senapati
, Hagop M. Kantarjian
, et al.
Figure S12 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial
2026
·
Jayastu Senapati
, Hagop M. Kantarjian
, et al.
Table SM1 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial
2026
·
Jayastu Senapati
, Hagop M. Kantarjian
, et al.
Figure S5 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial
2026
·
Jayastu Senapati
, Hagop M. Kantarjian
, et al.
Figure S15 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial
2026
·
Jayastu Senapati
, Hagop M. Kantarjian
, et al.
Figure S1 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial
2026
·
Jayastu Senapati
, Hagop M. Kantarjian
, et al.
Table S12 from Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial
2026
·
Jayastu Senapati
, Hagop M. Kantarjian
, et al.
Show more works
View as search
Works count:
49
Citation count:
118
H-index:
2
I10-index:
1
Year
Topic
Type